Milestone Bolsters Legal Team Amidst Cardamyst Commercialization
Event summary
- Milestone Pharmaceuticals appointed David Sandoval as General Counsel and Chief Compliance Officer, effective immediately.
- Sandoval’s appointment coincides with the launch of CARDAMYST™ (etripamil) nasal spray, approved by the FDA on December 12, 2025.
- Sandoval brings over 15 years of experience in legal and compliance within the life sciences sector, particularly in late-stage development and commercialization.
- Prior roles include Senior Vice President, General Counsel, Corporate Compliance Officer and Corporate Secretary at MaxCyte, Inc.
The big picture
The appointment of a seasoned legal and compliance officer like Sandoval signals Milestone's commitment to navigating the complexities of commercializing a novel pharmaceutical product in a highly regulated environment. This move is particularly important given the increasing emphasis on corporate governance and SEC compliance within the biopharmaceutical sector, where regulatory missteps can carry significant financial and reputational consequences. The timing aligns with the critical phase of CARDAMYST’s market entry and the need to establish a robust legal framework for long-term growth.
What we're watching
- Regulatory Headwinds
- The effectiveness of Sandoval’s compliance programs will be crucial given CARDAMYST’s novel delivery method and potential for scrutiny regarding patient self-administration.
- Execution Risk
- Milestone’s ability to scale operations and build infrastructure to support CARDAMYST’s commercialization will be heavily influenced by Sandoval’s legal and compliance expertise.
- Litigation Exposure
- Given the product's safety profile and potential for adverse events, the frequency and severity of any future litigation will be a key indicator of long-term value.
Related topics